Supernus Pharmaceuticals, Inc. Common Stock Earnings Dividend

Supernus Pharmaceuticals, Inc. Common Stock’s revenue jumped 38.63% since last year same period to $207.71Mn in the Q1 2026. On a quarterly growth basis, Supernus Pharmaceuticals, Inc. Common Stock has generated -1.83% fall in its revenue since last 3-months.

Supernus Pharmaceuticals, Inc. Common Stock’s net profit jumped 80.61% since last year same period to $-2.29Mn in the Q1 2026. On a quarterly growth basis, Supernus Pharmaceuticals, Inc. Common Stock has generated 44.14% jump in its net profits since last 3-months.

Supernus Pharmaceuticals, Inc. Common Stock’s net profit margin jumped 86.01% since last year same period to -1.1% in the Q1 2026. On a quarterly growth basis, Supernus Pharmaceuticals, Inc. Common Stock has generated 43.1% jump in its net profit margins since last 3-months.

Supernus Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current quarter stand at 0.3 - a 7.14% jump from last quarter’s estimates.

Supernus Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) estimates for the current year stand at 0.3.

Supernus Pharmaceuticals, Inc. Common Stock’s earning per share (EPS) fell -52.27% since last year same period to 0.21 in the Q1 2026. This indicates that the Supernus Pharmaceuticals, Inc. Common Stock has generated -52.27% annual rate of fall in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Supernus Pharmaceuticals, Inc. Common Stock’s return on assets (ROA) stands at 0.01.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Supernus Pharmaceuticals, Inc. Common Stock’s return on equity (ROE) stands at -0.03.